Abstract
Portopulmonary hypertension (POPH) is the presence of pulmonary arterial hypertension in patients with portal hypertension. Among liver transplant (LT) candidates, reported incidence rates of POPH range from 4.5% to 8.5%. In patients with LT, intraoperative death and immediate post-LT mortality are feared clinical events when transplantation is attempted in the setting of untreated, moderate to severe POPH; therefore, POPH precludes LT unless the mean pulmonary artery pressure can be reduced to a safe level and right ventricular function optimized. Specific pulmonary artery vasodilator medications seem effective in reducing pulmonary artery pressures and improving right ventricular function and survival.
Original language | English (US) |
---|---|
Pages (from-to) | 421-438 |
Number of pages | 18 |
Journal | Clinics in liver disease |
Volume | 18 |
Issue number | 2 |
DOIs | |
State | Published - May 2014 |
Keywords
- Cirrhosis
- Liver transplant
- Portal hypertension
- Portopulmonary hypertension
- Pulmonary hypertension
ASJC Scopus subject areas
- Hepatology